Introduction
============

Neuroblastoma (NBL) is a common solid tumor in children that originates from primordial neural crest cells ([@b1-ol-0-0-9985]). Despite multidisciplinary therapies, patients with high-risk NBL have a dismal prognosis. Recent genome-wide analyses have revealed *anaplastic lymphoma kinase (ALK)* gene alterations, amplification, and activating heterozygous mutations in the tyrosine kinase domain (TKD) in approximately 8% of primary NBLs ([@b2-ol-0-0-9985]--[@b5-ol-0-0-9985]). *ALK* mutations, often detected in heterozygous, are involved in cell proliferation and invasion and more frequently occur in high-risk and relapsed cases ([@b1-ol-0-0-9985],[@b6-ol-0-0-9985]), while homozygous *ALK* mutations are quite rare ([@b4-ol-0-0-9985],[@b7-ol-0-0-9985]). The discovery of *ALK* alterations provides the first tractable oncogenic target in NBL and facilitates the clinical application of ALK inhibitors, such as crizotinib ([@b8-ol-0-0-9985]). Here we present the case of a female patient with relapsed high-risk NBL harboring a heterozygous *ALK* F1245L mutation at the time of the initial diagnosis. This mutation became homozygous at relapse due to uniparental disomy (UPD), which was associated with aggressive tumor behavior after relapse. We further analyzed genetic alterations that may explain the molecular mechanism for NBL relapse.

Materials and methods
=====================

### Samples

Biopsy samples at primary and relapse were subjected to this analysis after receiving written, informed consent according to protocols approved by the Human Genome, Gene Analysis Research Ethics Committee of the University of Tokyo and St. Luke\'s International Hospital. No matched normal sample was available. Genomic DNA of each sample was isolated by NucleoSpin DNA RapidLyse kit (Macherey-Nagel Gmbh & Co., Düren, Germany) according to manufacturer\'s protocol.

### Direct sequencing

Direct sequencing of ALK was performed according to manufacturer\'s protocol with the use of an ABI 3500 Genetic Analyzer (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The following set of primers were used: ALK-24_F: GCTGCCCATGTTTACAGAATGC; ALK-24_R: TCCATCGAGGAACTTGCTAC; ALK-25_F: CTGGTGTAGCTGCATGTTC; ALK-25_R: CATCCTACATCCAAATGGCTC; ALK-26_F: AATCCTAGTGATGGCCGTTG; ALK-26_R: GGAGATGATGTAAGGGACAAGC.

### Targeted capture sequencing

Targeted capture was performed using a SureSelect custom kit (Agilent Technologies, Inc., Santa Clara, CA, USA) according to the manufacturer\'s protocol ([@b9-ol-0-0-9985]--[@b11-ol-0-0-9985]). The custom bait library was designed to include: i) all coding exons of 367 genes; ii) untranslated regions and introns of 16 genes (*CD274, CTNNB1, ERG, ETV1, ETV4, EWSR1, FEV, FLI1, FOXO1, FUS, INO80D, NCOA1, NCOA2, NOTCH1, PAX3*, and *PAX7*) for detecting breakpoints of structural variations; iii) 110,000 bases surrounding *TERT* for detecting *TERT* rearrangement; iv) promoter and enhancer regions of *FGFR3, MYC* and *TERT*; v) 11 microRNA genes (*MIR100, MIRLET7A1, MIRLET7A2, MIRLET7A3, MIRLET7B, MIRLET7C, MIRLET7D, MIRLET7E, MIRLET7F1, MIRLET7F2, MIRLET7G*), and vi) 3,527 SNP positions for copy number analysis. The total of 381 targeted genes and regions besides the SNP positions were selected to include: i) genes adopted in more than one of the following existing gene panels: MSK-IMPACT ([@b12-ol-0-0-9985]) CMS400 (Thermo Fisher Scientific, Inc.), FoundationOne (Foundation Medicine, Cambridge, MA, USA), Human Comprehensive Cancer Panel (Qiagen GmbH, Hilden, Germany); ii) the most frequently mutated 20 genes in each type of malignancy according to Catalogue of Somatic Mutations in Cancer (COSMIC) v78, and iii) genes that were recurrently affected in pediatric malignancies including neuroblastoma ([@b6-ol-0-0-9985],[@b13-ol-0-0-9985],[@b14-ol-0-0-9985]), hepatoblastoma ([@b15-ol-0-0-9985],[@b16-ol-0-0-9985]), pleuropulmonary blastoma ([@b17-ol-0-0-9985],[@b18-ol-0-0-9985]), rhabdomyosarcoma ([@b19-ol-0-0-9985],[@b20-ol-0-0-9985]), Ewing\'s sarcoma ([@b21-ol-0-0-9985],[@b22-ol-0-0-9985]), and germ cell tumor ([@b23-ol-0-0-9985]).

Captured targets were subjected to sequencing using a HiSeq 2000 (Illumina, Inc., San Diego, CA, USA) with a standard 125-bp pairedend read protocol according to the manufacturer\'s instructions ([@b24-ol-0-0-9985]). With mean depths of 383 and 381 in paired primary-relapse specimens, respectively, sequence alignment and mutation calling was performed using our in-house pipeline 'Genomon v.2.5.0', as previously described ([@b25-ol-0-0-9985]) in which reads that had either a mapping quality score of \<25, a base quality score of \<30, or five or more mismatched bases were excluded from the analysis. Candidate mutations with i) a variant allele frequency in tumor samples ≥0.1; and ii) a EBcall ([@b26-ol-0-0-9985]) (Empirical Bayesian mutation calling) P ≤1 ×10^−10^ was adopted and filtered by excluding i) synonymous mutations and variants without complete ORF information; ii) known variants listed in the 1000 Genomes Project (May 2011 release); NCBI SNP database (dbSNP) build 131; National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (ESP) 5400; the Human Genome Variation Database (HGVD; October 2013 release); or our in-house SNP database; iii) variants present only in unidirectional reads; iv) variants occurring in repetitive genomic regions; v) variants with \<5 supporting reads in tumor samples; and vi) all variants found in nonpaired normal samples (n=30) showing an allele frequency of \>0.0025. Putative structural variations were manually curated and further filtered by removing those with: i) \<20 supporting reads in tumor samples; ii) a VAF of \<0.10 in tumor samples; and iii) all variants found in normal samples. Finally, mapping errors were removed by visual inspection on the Integrative Genomics Viewer (IGV) browser ([@b27-ol-0-0-9985]).

### SNP Array Analysis

SNP array analysis was performed using GeneChip Human Mapping Cytoscan HD (Affymetrix; Thermo Fisher Scientific, Inc.). Genome-wide detection of copy number abnormalities or allelic imbalances was processed using Copy Number Analysis for Affymetrix GeneChip (CNAG)/Allele-Specific Copy Number using Anonymous References (AsCNAR) v3.5.1 software ([@b28-ol-0-0-9985]).

Results
=======

### Aggressive clinical course in a relapsed NBL patient

A 3-year-old girl was diagnosed with high-risk NBL of the left adrenal gland with bone and marrow metastases. Neuron specific enolase (NSE) and urine vanillylmandelic acid (VMA) levels were elevated (215 µg/l and 8.4 mg/l, respectively), and *MYCN* amplification was present. Immunohistochemical analyses revealed tumor cells positive for ALK. The patient received five courses of chemotherapy followed by high dose chemotherapy (busulfan and melphalan) with autologous hematopoietic stem cell transplantation, surgical gross total resection of the primary tumor, and radiation therapy to the tumor bed (19.8 Gy). The combination therapy successfully induced complete remission. However, 12 months after the diagnosis, she suffered from local tumor recurrence at the primary site. Two cycles of topotecan and cyclophosphamide (TC) and three of ifosfamide, cisplatin, and etoposide (ICE) gradually reduced the tumor size. After a fourth course of ICE, the tumor rapidly grew and urgent radiotherapy, with a combination of vincristine and irinotecan, was required. After obtaining approval from the institutional review board, crizotinib was administered for 28 days. Unfortunately, the tumor progressed and she succumbed to the disease ([Fig. 1](#f1-ol-0-0-9985){ref-type="fig"}).

### Molecular analysis of paired diagnosis-relapse samples

After obtaining informed consent from her guardians, DNA was extracted from biopsy samples of the adrenal tumor both at diagnosis and after relapse. Direct sequencing was performed to detect *ALK* mutations, and a F1245L mutation (c.T3733C; TTC\>TCC) was identified in both the sample at diagnosis and relapse, which is a common activating mutation in NBL. Intriguingly, the relapse sample exclusively contained the mutated allele, whereas the diagnosis sample clearly showed a heterozygous change ([Fig. 2A](#f2-ol-0-0-9985){ref-type="fig"}). In accordance with this, SNP arrays analysis in the relapse sample revealed acquired UPD of chromosome 2, including the *ALK* locus, in which the wild-type allele was likely to be lost by chromosomal mis-segregation with duplication of the mutated allele ([Fig. 2B and C](#f2-ol-0-0-9985){ref-type="fig"}). We also detected several shared copy number alterations in both the diagnosis and relapse samples, including a focal amplification of 2p24.2--24.3 comprising the *MYCN* locus ([Fig. 3](#f3-ol-0-0-9985){ref-type="fig"}). We further analyzed other genetic alterations, which might have been associated with disease recurrence and aggressiveness, using targeted capture sequencing (TCS) for 381 genes related to pediatric cancers (U-Tokyo Onco-panel v1). Because only tumor samples were analyzed, candidate mutations were filtered referring to our previous study ([@b25-ol-0-0-9985]), where we have confirmed the somatic mutations detected in TCS by using matched normal samples. We identified four and ten variants in the diagnosis and relapse samples, respectively ([Tables I](#tI-ol-0-0-9985){ref-type="table"} and [II](#tII-ol-0-0-9985){ref-type="table"}). All mutations detected at diagnosis were also detected in relapse sample. The *ALK* F1245L mutation was detected in both the diagnosis (variant allele frequency (VAF)=0.47) and relapse samples (VAF=0.83), which is consistent with other results showing duplication of *ALK* at relapse. Furthermore, alterations in *TSC2* (p.P1092fs), *PTPRD* (translocation to chromosome 6), *ATR* (p.T1310S), *AXL* (p.A549S), *ERG* (p.S315X), and *EZH2* (p.E204X) were acquired at relapse ([Fig. 4](#f4-ol-0-0-9985){ref-type="fig"}).

Discussion
==========

The *ALK* mutation hotspots are located within the intracellular TKD at codons F1174, R1275, and F1245, accounting for 85% of the *ALK* mutations found in NBL ([@b2-ol-0-0-9985]--[@b5-ol-0-0-9985]). Germline *ALK* mutations, such as R1275, have also been identified as the major cause of hereditary NBL; however, their penetrance has been considered relatively low ([@b29-ol-0-0-9985]--[@b31-ol-0-0-9985]). In contrast, other hotspot mutations (F1174 and F1245) are rarely observed in familial cases. These F1174 and F1245 germline mutations have been linked to severe neurocognitive defects and abnormalities ([@b30-ol-0-0-9985]), which is consistent with reports that mutations in F1174 and F1245 have strong effects on the nonphosphorylated ALK TKD activity ([@b5-ol-0-0-9985]). Because both F1174 and F1245 are located in the region inhibiting ligand-independent activation, they impair self-inhibition and enhance the tyrosine kinase activity ([@b32-ol-0-0-9985]).

We detected a heterozygous *ALK* F1245 mutation at diagnosis that became homozygous at relapse in the present case. Homozygous *ALK* mutations have been rarely reported as far ([@b4-ol-0-0-9985],[@b7-ol-0-0-9985]). This duplication at relapse may lead to growth advantage of tumor cells and be associated with disease progression. In fact, acquired UPD, resulting in the duplication of an oncogenic mutation, has been reported for various neoplasms. We have previously shown that the aggressive transformation of juvenile myelomonocytic leukemia is associated with the duplication of the oncogenic *KRAS* due to acquired UPD ([@b33-ol-0-0-9985]). Further, a previous report has revealed that the homozygous *ALK* F1174S mutation due to acquired UPD during the disease course may be responsible for the very rapid progress of NBL and resistance to chemotherapy ([@b7-ol-0-0-9985]). An enhanced oncogenic potential has also been reported in homozygous *EGFR* mutations on TKD in patients with non-small cell lung cancer, particularly in metastatic cases ([@b34-ol-0-0-9985]). Thus, homozygous TKD mutations are associated with an aggressive tumor progression in patients. In addition to the strong effects of the F1245 mutation on the ALK TKD activity, the bi-allelic presence of the *ALK* oncogenic mutation due to acquired UPD may have conferred further aggressiveness to the tumor during the relapse in this case.

In our comprehensive analysis, in addition to the *ALK* F1245 mutation and *MYCN* amplification, we also detected somatic oncogenic alterations comprising *PTPRD* (chromosomal rearrangement) and *TSC2* (p.P1092fs) at relapse. PTPRD is a member of a large family of protein tyrosine phosphatases and functions as a tumor suppressor by destabilizing aurora kinase A ([@b35-ol-0-0-9985]). The low expression of *PTPRD* is associated with high-risk NBL with *MYCN* amplification ([@b36-ol-0-0-9985]). *TSC2* is a tumor suppressor gene that is responsible for tuberous sclerosis, which is an autosomal dominant disorder characterized by the formation of hamartomas in various organs. The inactivation of TSC2 results in TSC1-TSC2 dissociation and markedly impairs the ability of TSC2 to inhibit mTOR signals, leading to cell proliferation and disease progression ([@b37-ol-0-0-9985]). A *TSC2* mutation has not been reported in patients with NBL. However, because alterations of *PTPRD* and *TSC2* occurred in a heterozygous setting, the functional relevance of these genes in the tumor progression of our case remains unclear. We also identified a truncated mutation of *EZH2* (p.E204X), which is an essential component of the polycomb repressive complex 2. The pathogenic role of the truncated mutation of *EZH2* is unclear because most *EZH2* mutations reported in NBL cases were gain of function mutations mediating the epigenetic silencing of a tumor suppressor ([@b38-ol-0-0-9985]).

In the present case, all detected single nucleotide variants were observed in the major clone (VAF \>0.35). None of acquired alterations at relapse were detected in primary sample even as the minor clone (VAF \<0.35), although there was a technical limitation on our TCS, which cannot detect mutations with low allele frequency (VAF \<0.05). Because no minor variants were detected, intratumor heterogeneity was not defined in the present case. Intratumor heterogeneity leads to selective outgrowth of clones that have a phenotypic advantage ([@b39-ol-0-0-9985]). The occurrence or presence of bi-allelic change of the *ALK* mutation due to acquired UPD and other acquired mutations such as *TSC2* and *PTPRD* might be involved in tumor relapse and chemo-resistance in the present cases.

We report a patient with relapsed NBL harboring *ALK* F1245 mutation, which was heterozygous at diagnosis and became homozygous at relapse with resistance to crizotinib. This duplication of *ALK* mutation was extremely rare, and may be associated with aggressive behavior after relapse in this case. As previously reported, the *ALK* F1245 mutations would be suggested to be relatively crizotinib-resistant ([@b5-ol-0-0-9985]). Although a clinical benefit of ALK inhibitors in patients with NBL has not been confirmed, more potent next-generation ALK inhibitors have been developed and clinical trials to estimate their efficacy are currently underway (NCT03107988) ([@b40-ol-0-0-9985],[@b41-ol-0-0-9985]). In future, a treatment based on the *ALK* mutation status will be promising.
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![Computed tomography imaging during the clinical course of the present case, (A) at diagnosis of relapsed neuroblastoma, (B) before administration of crizotinib, and (C) 28 d after the initiation of crizotinib.](ol-17-03-3323-g00){#f1-ol-0-0-9985}

![(A) *ALK* (NM_004304) F1245L mutation status by direct sequencing at diagnosis (heterozygous) and after relapse (homozygous). Copy number analysis using a SNP array for chromosome 2 including the (B) *ALK* gene region in diagnosis and (C) relapse samples. Red dots at the top represent the signal from each probe (raw data), and blue line indicates the moving average of red dots. Red and green lines at the bottom represent allele-specific copy number. UPD was observed in the relapse sample. UPD, niparental disomy.](ol-17-03-3323-g01){#f2-ol-0-0-9985}

![Results of SNP array analysis in (A) primary sample and (B) relapsed sample. Colorful dots at the top represent signal of each probe (raw data). Red and green lines at the bottom show allele specific copy number.](ol-17-03-3323-g02){#f3-ol-0-0-9985}

![Results of the genomic analysis and hypothetical model of aggressive progression in this case. A heterozygous *ALK* F1245 mutation was detected at diagnosis. This mutation became homozygous at relapse due to acquired UPD at chromosome 2, leading to both the duplication of the mutant allele and loss of the wild type allele. The duplication might be due to clonal evolution, acquired later in the process of relapse. UPD, uniparental disomy.](ol-17-03-3323-g03){#f4-ol-0-0-9985}

###### 

Mutation calls of targeted capture sequencing.

  Sample    Chr   Start       End         Ref   Alt   Gene      Mutation type   Amino acid change                           VAF
  --------- ----- ----------- ----------- ----- ----- --------- --------------- ------------------------------------------- -------
  Primary   2     29436860    29436860    A     G     *ALK*     SNV             NM_004304:exon24:c.T3733C:p.F1245L          0.469
  Relapse   2     29436860    29436860    A     G     *ALK*     SNV             NM_004304:exon24:c.T3733C:p.F1245L          0.825
  Relapse   3     142253938   142253938   G     C     *ATR*     SNV             NM_001184:exon21:c.C3929G:p.T1310S          0.409
  Primary   5     180043943   180043943   C     G     *FLT4*    SNV             NM_182925:exon22:c.G3053C:p.S1018T          0.425
  Relapse   5     180043943   180043943   C     G     *FLT4*    SNV             NM_182925:exon22:c.G3053C:p.S1018T          0.496
  Relapse   7     148525847   148525847   C     A     *EZH2*    Stopgain        NM_001203247:exon6:c.G610T:p.E204X          0.387
  Relapse   16    2129420     2129420     −     G     *TSC2*    Frameshift      NM_000548:exon28:c.3276dupG:p. P1092fs      0.245
  Primary   17    10361019    10361019    C     A     *MYH4*    Stopgain        NM_017533:exon16:c.G1615T:p.E539X           1
  Relapse   17    10361019    10361019    C     A     *MYH4*    Stopgain        NM_017533:exon16:c.G1615T:p.E539X           0.7
  Relapse   19    41754659    41754660    CG    TC    *AXL*     SNV             NM_021913:exon14:c.CG1644_1645TC: p.A549S   0.429
  Primary   21    32493125    32493125    C     G     *TIAM1*   SNV             NM_003253:exon29:c.G4337C:p.R1446T          0.506
  Relapse   21    39772318    39772318    G     T     *ERG*     Stopgain        NM_001291391:exon8:c.C944A:p.S315X          0.43
  Relapse   21    32493125    32493125    C     G     *TIAM1*     SNV           NM_003253:exon29:c.G4337C:p.R1446T          0.552

Chr, chromosome; SNV, single nucleotide variant; VAF, variant allele frequency

###### 

Structural variant call of targeted capture sequencing.

  Sample    Chr Gene 1   Position Gene 1   Direction Gene 1   Chr Gene 2   Position Gene 2   Direction Gene 2   Variant type    Gene 1   Gene 2    VAF
  --------- ------------ ----------------- ------------------ ------------ ----------------- ------------------ --------------- -------- --------- --------
  Relapse   6            138269463         −                  9            8338848           −                  Translocation   −        *PTPRD*   0.5745

Chr, chromosome; VAF, variant allele frequency
